Objective: To evaluate photographic measures of cytomegalovirus (CMV) retinitis as surrogate outcomes for changes in vision in patients with CMV retinitis related to the acquired immunodefiency syndrome.
P
IVOTAL EFFICACY trials supporting the approval of treatments for cytomegalovirus (CMV) retinitis were designed to compare time to retinitis progression as assessed from photographs between patients randomly assigned to immediate treatment or to deferral of treatment. [1] [2] [3] [4] [5] [6] Retinitis progression was defined as 750 µm or more of movement along the border of an existing lesion or the appearance of a new lesion in either eye. Assessments of progression made from photographs by graders unaware of treatment assignment have proven to be a more reliable and sensitive method than assessments made by clinicians based on ophthalmoscopic examinations. 2, 7, 8 Movement of 750 µm or more is a sensitive measure of retinitis advancement selected to protect patients assigned to deferral of therapy from clinically important vision loss.
The goal of retinitis treatment is to preserve vision. Despite the widespread use of photographic assessments of retinitis progression as a primary outcome measure in clinical trials, it has not been evaluated as a surrogate outcome for change in vision. The purpose of the current study was to evaluate progression as well as an alternative retinitis measure assessed from photographs, change in area of retina involved with retinitis, as surrogate outcomes for declines in visual acuity and visual field.
Prentice and others have proposed criteria by which to evaluate proposed surrogate outcomes. [9] [10] [11] [12] To evaluate the retinitis measures as surrogates for changes in vision, we operationalized those criteria as follows: (1) association to vision loss; (2) the degree to which the measure accounted for treatment-related differences in vision measures; (3) completeness of data; and (4) sample size requirements. The first 2 criteria evaluate the association between a surrogate and a clinical outcome in general and with respect to treatment-related changes in these measures, respectively. The final criteria are related to the feasibility and practicality of the surrogate outcome. 8, [13] [14] [15] Patients with newly diagnosed retinitis or relapsed retinitis enrolled in these trials over a 7-year period (1990) (1991) (1992) (1993) (1994) (1995) (1996) .
EPIDEMIOLOGY AND BIOSTATISTICS

RESULTS
BASELINE CHARACTERISTICS OF PATIENTS
Two hundred thirty-four patients with newly diagnosed retinitis were enrolled in the FGCRT; 279 patients with relapsed retinitis were enrolled in the CRRT; 209 patients (83 patients with newly diagnosed retinitis and 126 with relapsed retinitis) were enrolled in the MACRT. The analyses presented herein included data from 88% to 95% of patients enrolled in these trials (ie, those patients who had baseline and follow-up photographic data available for at least 1 eye with CMV retinitis at baseline) ( Table 1) . Eight patients were enrolled in more than 1 of the trials; separate data were collected for each trial in which they were enrolled.
Patients enrolled in the 3 trials had similar demographic profiles with the exception that relatively more whites were enrolled in the FGCRT (Table 1) . Relatively more patients enrolled in the most recent trial, the MACRT, received combinations of antiretrovirals, and those were
MATERIALS AND METHODS
TRIAL PROTOCOLS
The protocols for all 3 trials were reviewed and approved by institutional review boards at the coordinating center and at the clinical centers; all patients signed institutional review board-approved consent statements. Details on the study designs, procedures, and results are described elsewhere. 8, [13] [14] [15] [16] [17] 
PHOTOGRAPHIC MEASURES OF RETINITIS
For these analyses, progression was defined as the movement of a border 750 µm or greater along a front 750 µm or more in length, or the occurrence of a new lesion 750 µm or greater in diameter and separated from a previous lesion by 750 µm or more, in a previously uninvolved eye. Fundus Photograph Reading Center (FPRC) graders unaware of treatment assignment assessed progression by comparison of photographs taken at baseline to those taken at follow-up visits.
The extent of retinitis was evaluated from fundus photographs by measuring the area of retina with retinitis in zones 1 and 2; zone 3 was not evaluated because it could not be photographed reliably. The definition of retinal zones has been described. 18 Area of retina involved was expressed as a percentage (ie, area of retina in zones 1 and 2 with retinitis divided by total area of retina in zones 1 and 2). In the FGCRT, retinal area involved was determined by FPRC graders from planimetric measurements on a digitized mosaic of the retina created from fundus photographs. 19 In the CRRT and the MACRT, FPRC graders evaluated the area of retina involved using grids superimposed on the photographs.
VISION MEASURES
The vision measures were visual acuity as measured on logarithmic charts developed for the Early Treatment Diabetic Retinopathy Study 20 and visual field as measured via kinetic perimetry along 12 meridians on a Goldmann Visual Field Test with a IV4e test object; the degrees of field seen along each meridian were summed to calculate the visual field score.
21
ANALYSIS
Data collected at visits that occurred during the first year of follow-up before or after the treatment protocols were suspended were included in these analyses.
For most analyses, data were limited to eyes with CMV retinitis at baseline as determined from FPRC evaluation of photographs. Baseline characteristics of involved eyes were summarized from standardized evaluations of photographs by FPRC graders as previously described. 20 For the MACRT, initial treatment for CMV retinitis was defined as the primary treatment recorded at the baseline visit. Time-dependent variables for the retinitis measures (progression status and change in retinal area involved with retinitis) were defined as the value at the same visit at which vision measures were evaluated or at the most recent prior visit. For progression, once the event occurred the value of the time-dependent variable did not change.
For event-type measures (progression and visual acuity decline), median times to event were estimated according to the Kaplan-Meier method and Cox proportional hazards models were used to estimate relative risks (RRs). 22, 23 For baseline characteristics, P values associated with RRs of events were derived using procedures for estimating variance of correlated data (2 eyes from 1 patient). 24 No corrections for correlated data were made for models including time-dependent covariates. Continuous outcomes were modeled with linear regression using general estimating equation procedures, which accounted for correlations among repeated observations from an eye. 25 Analyses of associations of retinitis measures to vision measures were performed by trial and stage of retinitis (newly diagnosed or relapsed) because of the large variability in event rates across trials. If appropriate, data were combined for overall estimates of the associations.
The capacity of a retinitis measure to account for the treatment effect on visual field was evaluated by comparing the linear regression coefficient for CMV treatment estimated from a model without the time-dependent retinitis measure with those from a model that included the measure. 9, 12 The deviance scores (−2 log likelihood statistics) were used to compare the predictive value of the retinitis measures for visual acuity decline and visual field decline. 23, 26 These analyses were performed on the subgroup of involved eyes for which data on all measures of retinitis were available.
Sample size estimates were made for event-type outcomes with log rank tests and for continuous outcomes with t test procedures. 27, 28 Because of secular trends in event rates and mean changes, event rates, means, and SDs were estimated based on MACRT data. 
BASELINE CHARACTERISTICS OF EYES WITH RETINITIS
Characteristics of involved eyes that were different among the trials after adjustment for stage of retinitis were zone 1 involvement, activity, and microangiopathy (hemorrhage/microaneurysms and cotton-wool spots) ( Table 2) . Involved eyes of patients with newly diagnosed retinitis had smaller, more active lesions and greater percentages with cotton-wool spots, vitreous hemorrhage, and retinitis involvement of the optic disc than involved eyes of patients with relapsed retinitis (Table 2) .
PROGRESSION IN INVOLVED EYES
Data to evaluate progression in involved eyes were available for 88% to 96% of involved eyes of patients enrolled in the 3 trials. Median times to progression differed among the 3 trials (Table 3 ) (P=.001) (Figure 1 ), but were similar for eyes of newly diagnosed and relapsed retinitis after adjustment for trial and initial CMV treatment (Table 3 ) (P=.19). Initial treatment for CMV retinitis was not associated with risk of progression in the FGCRT (IV ganciclovir vs IV foscarnet), but was associated in the CRRT (PϽ.001) and MACRT (P=.007). In the CRRT, the median times to first progression while receiving treatment in involved eyes were 2.5, 2.0, and 5.1 months for the IV ganciclovir, IV foscarnet, and IV combination treatment groups, respectively. In the MACRT, the median times to first progression were 2.7, 6.2, and 5.8 months for patients receiving IV or oral systemic monotherapy, IV combination therapy, or local therapy, respectively.
AREA OF RETINA (ZONES 1 AND 2) WITH RETINITIS IN INVOLVED EYES
Data to evaluate the percentage of retinal area involved with retinitis at baseline and during follow-up were available for 55% to 68% of involved eyes. The mean rates of change in retinal area involved with retinitis, expressed §P values were derived from logistic regression models for binary variables and from linear regression models for continuous variables; all models included trial and stage of retinitis as covariates.
The denominators for patient characteristics vary because of missing data. ¶For analysis, categories were collapsed to white vs other for race. #Bilateral disease was defined by clinician or Fundus Photograph Reading Center evaluation at baseline.
as a percentage of zones 1 and 2, for the first 6 months of follow-up differed among the trials (Table 3 ) (PϽ.001): the rates were 3.5%, 2.6%, and 1.4% of retinal area per month in the FGCRT, CRRT, and MACRT, respectively. Change in area during follow-up was similar for eyes of patients with newly diagnosed and relapsed retinitis (Table 3 ) (P= .81). Change in the percentage of retinal area involved with retinitis was related to treatment for CMV retinitis in the MACRT (PϽ.001), and there was a suggestion that it was in the CRRT (P=.08), but not in the FGCRT (Table 3 ). In the CRRT, IV ganciclovir therapy was associated with a mean increase in the percentage of retinal area involved with retinitis over the first 6 months of follow-up of 1.9% compared with IV combination therapy; IV foscarnet was associated with an increase of 1.3% compared with IV ganciclovir. For example, the estimated mean increases in retinal area involved after 6 months of follow-up were 15.2%, 13.3%, and 16.5% for IV ganciclovir, IV combination, and IV foscarnet, respectively. In the MACRT, IV or oral systemic monotherapy was associated with a mean increase of 5.2% as compared with IV combination therapy and an increase of 4.6% as compared with local therapy. After 6 months, the mean increases in retinal area with retinitis for involved eyes of newly diagnosed patients were 10.1%, 4.9%, and 5.4% for monotherapy, IV combination therapy, and local therapy, respectively.
VISUAL ACUITY DECLINE IN INVOLVED EYES
Visual acuity results from follow-up were available on 88% to 94% of involved eyes. After adjustment for stage of retinitis and initial treatment for CMV, the median times to decline in visual acuity of 15 letters or more on an Early Treatment Diabetic Retinopathy Study chart (eg, going from 20/20 to 20/40 in Snellen equivalents) differed among the trials (Table 3 ) (P = .02) (Figure 1 ). Involved eyes of patients with newly diagnosed and relapsed retinitis had similar risks of events (Table 3 ) (P =.45). Initial treatment for CMV retinitis did not influence the risk of visual acuity decline in any of the trials (Table 3) . §P values were derived from logistic regression models for binary variables and from linear regression models for continuous variables, and were adjusted for trial and stage of retinitis. Variance estimates were adjusted for correlated data (2 eyes from 1 patient). 26 The denominators for ocular characteristics vary because of missing data. ¶P values were derived from test without adjustment for other factors. #Median visual field in all uninvolved eyes was 719°. 
VISUAL FIELD CHANGE IN INVOLVED EYES
Visual field data were available on 64% to 82% of involved eyes. The rate of visual field loss differed among the 3 trials (Table 3 ) (PϽ.001). However, the rate of visual field loss was similar for involved eyes of patients with newly diagnosed and relapsed retinitis (Table 3 ) (P=.46).
In the FGCRT and CRRT, visual field loss during follow-up was not associated with initial treatment for CMV retinitis (Table 3 ). In the MACRT, there were treatmentrelated differences in visual field loss for all involved eyes (P=.01) ( Table 3 ). Initial treatment with IV systemic combination therapy was associated with a smaller decline in visual field over follow-up (mean, 48.0°less) than the decline in the IV or oral systemic monotherapy group. Local therapy also tended to be associated with a smaller overall decline in visual field than in the systemic monotherapy group (mean, 27.4°less). The estimated mean decreases in visual field for involved eyes of patients with newly diagnosed retinitis over 12 months were 117.0°, 69.1°, and 89.0°for monotherapy, IV combination therapy, and local therapy, respectively.
ASSOCIATIONS BETWEEN RETINITIS MEASURES AND VISUAL ACUITY LOSS
Overall, progression was associated with about a doubling of the risk of a decline in visual acuity of 15 or more letters ( †CMV prescription refers to initial treatments for CMV retinitis. The P value is for differences in the risk of event (progression or visual acuity loss) or for change over time (change in area or visual fields) associated with initial CMV prescriptions. If appropriate, the model was adjusted for baseline value (visual acuity, area of retina, or visual field) and follow-up time (change in area or visual field). Initial prescriptions were intravenous foscarnet vs intravenous ganciclovir for the FGCRT; intravenous foscarnet vs intravenous ganciclovir for the CRRT; and intravenous or oral monotherapy (ganciclovir, foscarnet, or cidofovir) vs intravenous combination therapy vs local therapy (ganciclovir implant or intravitreal injections of ganciclovir, foscarnet, or cidofovir) for the MACRT.
‡The P value indicates the differences among trials, adjusted for stage of retinitis (newly diagnosed vs relapsed) and initial CMV treatment. §The P value indicates the difference between eyes of patients with newly diagnosed and relapsed retinitis, adjusted for trial and primary CMV treatment. Not calculated because there were no events in the intravenous combination therapy group.
(REPRINTED) ARCH OPHTHALMOL / VOL 119, APR 2001 WWW.ARCHOPHTHALMOL.COM 558 (P = .62) but differed among the trials (Table 4 ) (P=.001). In the FGCRT and MACRT, a 10% increase in area involved with retinitis was associated with a 1.3 (PϽ.001) and 1.9 (combined MACRT data, P = .01) increase in the risk of the event, but there was no association of change in area with visual acuity decline in the CRRT.
The strength of the associations of time-dependent retinitis measures to visual acuity decline were compared based on the deviance score (−2 log likelihood statistic); larger deviance scores indicated that the retinitis measure explained more of the variability in the outcome. Because the patterns of missing data were different for each retinitis measure, the deviance scores were calculated for the subgroup of eyes for which data on all retinitis measures were available, effectively those with data on retinal area involved. The RRs for each time-dependent retinitis measure estimated from these subgroups were consistent with the RRs estimated from all available data (data not shown). Change in area of retina involved with retinitis was more predictive of visual acuity decline than progression in the FGCRT and MACRT (Table 4 ). In the CRRT, progression was more predictive than change in area.
ASSOCIATIONS BETWEEN RETINITIS MEASURES AND VISUAL FIELD LOSS
Overall, the average decline in visual field associated with retinitis progression was 75.1° (Table 4 ) (PϽ.001). The associations were not different across trials (Table 4) (P=.53) or by stage of retinitis (Table 4 ) (P =.86). Change in the percentage of retinal area involved also was associated with change in visual field (Table 4 ) (Figure 2) . Overall, the average decline in visual field associated with an increase of retinal area involved by 10% was 52.1° (Table 4 ) (PϽ.001). The associations were similar across trials (Table 4 ) (P=.25), but tended to be larger for involved eyes of relapsed patients (Table 4 ) (P=.06).
The strength of the associations between retinitis measures and visual field loss were compared with deviance scores. In all groups, change in area of retina involved with retinitis was more predictive of decline in visual field than progression (Table 4) .
ASSOCIATION BETWEEN TREATMENT EFFECTS ON RETINITIS AND VISION MEASURES
In these analyses the only observed treatment effect on a vision measure was in the MACRT. Systemic combi- nation therapy was associated with a smaller decline in visual field than systemic monotherapy. To evaluate how much of the treatment-related differences in visual field were accounted for by an intermediate retinitis measure (ie, progression or change in area involved), the treatment effect on visual field was estimated in models without and with a covariate for the time-dependent retinitis measure ( Table 5) . In model 1, which does not include a time-dependent retinitis measure, systemic combination therapy was associated with a smaller loss of visual field (mean, 48.0°less), than treatment with systemic monotherapy. Inclusion of progression as a timedependent covariate in the model (model 2) resulted in a 50% reduction in the average treatment effect associated with combination systemic treatment (ie, from −48.0°t o −23.9°), and the treatment effect was no longer significant. Inclusion of change in area of retina involved with retinitis in the model (model 3) resulted in a 66% reduction of the treatment effect, and the effect was no longer significant. Therefore, each measure accounted for some of the treatment-related differences in visual field, but change in area seemed to capture more of the effect.
SAMPLE SIZE
Estimates of the sample size required to detect 50% differences in outcome (ie, an RR of 1.5 or a 50% change in continuous measure), for a clinical trial of 2 treatments were 182 patients for progression, 226 for change in area involved with retinitis, 312 for visual acuity loss (Ն15 letters), and 352 for change in visual field.
COMMENT
The criteria used to evaluate measures of retinitis as surrogate outcomes for visual function measures were how well †The RR of visual acuity event associated with retinitis measure; retinitis measures were defined in a time-dependent fashion as either progression status (yes/no) or an increase in the area of zones 1 and 2 involved with retinitis of 10%. The RRs for individual trials and subgroups are unadjusted; the overall RR estimate from combined data ("All" column) is adjusted for trial and stage of retinitis.
‡The P value is derived from Wald tests for RR and ␤ coefficients. §For proportional hazards models (visual acuity), the deviance score (−2 log likelihood) is the difference between the log likelihood for a model without covariates and one including the time-dependent measure. For linear regression models (decrease in visual field), the deviance score is the difference in the log likelihood for a model with baseline visual field and follow-up time as covariates and one with those covariates and the time-dependent retinitis measure. The deviance score follows a 2 with 1 df. The P values are for tests of differences in the associations of retinitis measures and the vision outcome among the trials (ie, interaction by trial). ¶The P values are for tests of differences in the associations of retinitis measure and the vision outcome by stage of retinitis (newly diagnosed and relapsed) across all trials (ie, interaction by stage of retinitis).
#Indicates the overall estimate, and P value is not calculated because of differences in the associations among trials (ie, interaction by trial). **␤ indicates the regression coefficient from linear regression model for retinitis measure association with visual field loss (degrees) adjusted for baseline visual field and follow-up time; the overall ␤ estimates ("All" column) were adjusted for trial and stage of retinitis as well.
the measure predicted changes in visual function, how well treatment-related changes in vision outcomes were accounted for by changes in the measure, the completeness of data collection, and the sample size required for trials. Results for the 2 measures are summarized in Table 6 .
Change in retinal area involved was more predictive of visual acuity decline for involved eyes than progression (Table 4) . However, the association was not uniform; it was not associated with visual acuity decline in the involved eyes of patients with relapsed retinitis enrolled in the CRRT. On average, these eyes had the largest area involved with retinitis, and the highest rate of inner zone 1 involvement (Table 2) . Therefore, relatively small increases in retinal area involved may have had detrimental effects on visual acuity thereby attenuating the association. Change in area involved with retinitis was a stronger predictor of visual field decline than progression and the associations were uniform across trials and by stage of retinitis (Table 4) .
In the MACRT, change in area of retina involved with retinitis accounted for a larger portion of the treatment effect on visual field (66%) than progression (50%) ( Table  5) . Although the confidence intervals on these proportions may be large, 11, 12 the ranking is likely to be correct and is consistent with the observed associations of the retinitis measures to visual field loss (Table 4) . Area of retina involved is a continuous measure able to incorporate both spatial and temporal aspects of retinitis spread, unlike the threshold measurement of progression.
Even with up to 1 year of follow-up, observed treatment effects on retinitis measures were not uniformly followed by treatment effects on visual function measures. Does the lack of consistent treatment effects on both types of measures indicate that retinitis measures are not good surrogate outcomes? We think not. Effects on visual acuity are likely to be influenced by location of retinitis. Eyes with retinitis in zone 1 are more likely to lose visual acuity regardless of the status of retinitis measures (data not shown). Furthermore, the Studies of Ocular Complications of AIDS protocols included safeguards against visual acuity loss that made it less likely that treatmentrelated differences would be observed. In the CRRT, a treatment effect on visual field was observed in the primary results of the trial.
14 That analysis included all data collected before protocol suspension, whereas the present analysis included data collected during the first year of follow-up, regardless of whether the visits occurred before or up to 6 months after the protocol was suspended. The latter approach may have emphasized incongruities between treatment effects on retinitis and vision measures because of treatment modifications during follow-up. In the CRRT, patients assigned to the combination of IV ganciclovir and foscarnet were more likely to have treatment-related toxic effects and switch to monotherapy, 14 and patients receiving monotherapy who progressed were likely to receive combination therapy, especially after the treatment protocol was suspended. These results highlight another potential advantage of a valid surrogate outcome-the ability to measure treatment response before irreparable harm to the patient occurs.
Data on progression were available for at least 1 follow-up visit for most involved eyes (93% overall), whereas available data on area of retina involved with retinitis were fewer (64% overall). Two factors that contributed to that high rate of missing data were less frequent assessments of retinal area involved and photograph quality. Area assessments were done less frequently because they required more time. Photograph quality is more critical for evaluating retinal area involved because the 10 photographs must overlap appropriately to document all of zones 1 and 2, and all of the photographs must be of good quality. Data on retinal area involved from 19% of photograph sets were not used because more than 10% of zones 1 and 2 could not be graded, whereas only 9% of photograph sets could not be graded for progression.
The sample size estimates were smallest for trials with progression as the design outcome, which required 13% fewer patients than if change in area involved was the design outcome and at least 40% fewer than required for change in visual function. Change in area involved with *␤ is the regression coefficient for the difference in mean visual field loss (in degrees) between the treatment and systemic monotherapy (reference) adjusted for baseline visual field, follow-up time, stage of retinitis, and, in models 2 and 3, the time-dependent retinitis measure indicated by the column heading.
†P value for adjusted ␤ estimate derived from Wald test using robust variance estimates. ‡Reference category: this category included 98, 25, 1, and 3 involved eyes of patients whose initial cytomegalovirus treatment was intravenous ganciclovir, intravenous foscarnet, oral ganciclovir, or intravenous cidofovir, respectively. §Combination therapy: this category included 23 involved eyes of patients whose initial cytomegalovirus treatment was intravenous ganciclovir and intravenous foscarnet.
Local therapy: this category included 9 and 10 involved eyes of patients whose initial cytomegalovirus treatment was ganciclovir implants or intravitreal injections of ganciclovir, foscarnet, or cidofovir, respectively.
¶Time-dependent measure of retinitis advancement: Fundus Photograph Reading Center−assessed progression of Ն750 µm (model 2); and change in area of retina involved with retinitis from baseline (model 3). 
